Xencor XNCR 深 沪
等待开盘 08-29 09:30:00 美东时间
8.01
-0.010
-0.12%
华盛通- 最 高8.33
- 今 开8.11
- 成交量 21.78万股
- 最 低 7.98
- 昨 收 8.02
- 总市值 5.70亿
- 52周最高 27.24
- 市盈率 静 --
- 换手率 0.31%
- 52周最低 6.92
- 委 比 -72.61%
- 总股本 7117.08万
- 历史最高 58.345
- 量 比 0.31
- 振 幅 4.36%
- 历史最低 5.75
- 每 手 1
- 风险率 6.27%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多RBC Capital Maintains Outperform on Xencor, Lowers Price Target to $15
RBC Capital analyst Leonid Timashev maintains Xencor (NASDAQ:XNCR) with a Outperform and lowers the price target from $32 to $15.
08-21 22:17
Biotech sector slips amid reported return of ousted FDA official
Shares of several biotech firms fell in premarket trading Monday after reports that ousted U.S. Food and Drug Administration vaccine regulator Vinay Prasad will return to the agency. Prasad, who had o...
08-11 18:25
Wedbush Maintains Outperform on Xencor, Lowers Price Target to $26
Wedbush analyst David Nierengarten maintains Xencor (NASDAQ:XNCR) with a Outperform and lowers the price target from $31 to $26.
08-07 20:39
Xencor Q2 EPS $(0.41) Beats $(0.72) Estimate, Sales $43.61M Beat $21.45M Estimate
Xencor (NASDAQ:XNCR) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.72) by 43.06 percent. This is a 61.68 percent increase over losses of $(1.07) per share from the same
08-07 04:43
Avacta Appoints Dr. David Liebowitz as Chief Medical Officer to Lead Cancer Drug Strategy
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announces the appointment of David Liebowitz, M.D., Ph.D. as Chief Medical Officer (CMO) and Yulii
07-01 19:04
美股大行评级 | 潜在涨幅754.7%！HC Wainwright & Co.：Alector获机构升目标价至10美元，维持"买入"评级
潜在涨幅754.7%！HC Wainwright & Co.：Alector获机构升目标价至10美元，维持"买入"评级
05-10 10:00
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Polyrizon (NASDAQ:PLRZ) stock moved upwards by 57.1% to $0.58 during F...
05-10 05:06
Barclays Maintains Underweight on Xencor, Lowers Price Target to $6
Barclays analyst Peter Lawson maintains Xencor (NASDAQ:XNCR) with a Underweight and lowers the price target from $22 to $6.
05-09 00:43
Xencor Announces Executive Vice President Resignation
Xencor ( ($XNCR) ) has provided an announcement. On May 5, 2025, Xencor announc...
05-08 04:50
Xencor Q1 EPS $(0.66) Misses $(0.60) Estimate, Sales $32.73M Beat $22.41M Estimate
Xencor (NASDAQ:XNCR) reported quarterly losses of $(0.66) per share which missed the analyst consensus estimate of $(0.60) by 10 percent. This is a 40.54 percent increase over losses of $(1.11) per share from the same
05-08 04:50
